GlassScriptPhysician profile
Erin E Stewart
NPI 1699221333
$6,263.24
in general payments reported to CMS, 2019-2025
49 companies · $989 in 2025
The $989 reported for 2025 was more than what 87% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,081 · 2022: $1,318 · 2023: $1,400 · 2024: $1,476 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,864.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,099.04 | 2021-2025 | |
| Novo Nordisk INC | $941.79 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $448.27 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $433.99 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $402.97 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $313.21 | 2021-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.46 | 2021-2024 | Tradjenta, Jardiance |
| Astellas Pharma US INC | $211.77 | 2021-2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.70 | 2021-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $168.41 | 2021-2025 | Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $140.15 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $134.54 | 2021-2025 | Rexulti |
| Pfizer INC. | $117.18 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $107.03 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.58 | 2021-2024 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $94.49 | 2021-2023 | Hetlioz |
| Inspire Medical Systems, INC. | $89.38 | 2023 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $82.83 | 2021-2024 | Eliquis |
| Dexcom, INC. | $80.47 | 2021-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $69.12 | 2024-2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $63.27 | 2021-2022 | |
| Esperion Therapeutics, INC. | $53.68 | 2021-2022 | |
| Lundbeck LLC | $50.75 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $47.99 | 2021-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $47.88 | 2021-2024 | Gardasil, Gardasil 9, Capvaxive |
| Axsome Therapeutics, INC. | $43.75 | 2024 | Auvelity |
| Mylan Specialty L.P. | $42.44 | 2022-2023 | Yupelri |
| Philips North America LLC | $37.61 | 2024 | (Ck6) Holter |
| Amarin Pharma, INC. | $32.83 | 2021 | |
| Viatris Specialty LLC | $31.20 | 2025 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $30.04 | 2021 | |
| Amneal Pharmaceuticals LLC | $27.68 | 2024 | Unithroid |
| Sumitomo Pharma America, INC. | $27.36 | 2024 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $25.63 | 2022 | |
| Horizon Therapeutics Plc | $24.37 | 2021 | |
| Alk-Abello, INC | $24.04 | 2025 | Ragwitek, Odactra, Grastek |
| Eisai INC. | $21.28 | 2021 | |
| Daiichi Sankyo INC. | $21.10 | 2023 | Injectafer |
| Baxter Healthcare | $19.99 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Boston Scientific Corporation | $19.51 | 2024 | Watchman Access System |
| Actelion Pharmaceuticals US, INC. | $19.33 | 2025 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $19.20 | 2022 | |
| Dynavax Technologies Corporation | $18.24 | 2022 | |
| Seqirus USA INC | $18.15 | 2022 | |
| Edwards Lifesciences Corporation | $17.13 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.08 | 2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $16.38 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.20 | 2022 | |
| Medtronic, INC. | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.